Back to Search
Start Over
Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
- Source :
-
Circulation. Cardiovascular quality and outcomes [Circ Cardiovasc Qual Outcomes] 2020 Jan; Vol. 13 (1), pp. e006019. Date of Electronic Publication: 2020 Jan 10. - Publication Year :
- 2020
- Subjects :
- Anticholesteremic Agents adverse effects
Anticholesteremic Agents economics
Biomarkers blood
Cardiovascular Diseases diagnosis
Cardiovascular Diseases economics
Cardiovascular Diseases epidemiology
Cost-Benefit Analysis
Databases, Factual
Drug Costs
Dyslipidemias diagnosis
Dyslipidemias economics
Dyslipidemias epidemiology
Humans
Lipids blood
Practice Patterns, Physicians' economics
Randomized Controlled Trials as Topic
Risk Factors
Serine Proteinase Inhibitors adverse effects
Serine Proteinase Inhibitors economics
Treatment Outcome
United States epidemiology
Anticholesteremic Agents therapeutic use
Cardiovascular Diseases prevention & control
Drug Approval economics
Dyslipidemias drug therapy
PCSK9 Inhibitors
Practice Patterns, Physicians' trends
Serine Proteinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1941-7705
- Volume :
- 13
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Circulation. Cardiovascular quality and outcomes
- Publication Type :
- Academic Journal
- Accession number :
- 31918581
- Full Text :
- https://doi.org/10.1161/CIRCOUTCOMES.119.006019